In PC, FAK overexpression correlates with invasive behavior and poor prognosis, and pharmacologic FAK inhibition suppresses tumor cell motility and enhances the efficacy of taxane-based chemotherapy, implicating FAK as a mediator of both metastatic progression and therapy resistance [44,136,137,138,139,140]. Here, PTK2 is linked to neoplasm.